Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2021 Filed Jul 2, 2021 20:10 UTC |
DOTSON JERROLD DUANEVP, CFO AND SECRETARY
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 78,918 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001415889-21-003391 · form4-07022021_040729.xml · derivative · entry 7 DOTSON JERROLD DUANE · CIK 0001388853 · VP, CFO AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,375 Underlying: Common Stock · 113,293 shares Expires 2029-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to this stock option vested May 23, 2019, with the the remaining shares vesting in 1/36th installments on each monthly anniversary thereafter. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:10 UTC |
DOTSON JERROLD DUANEVP, CFO AND SECRETARY
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 36,707 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001415889-21-003391 · form4-07022021_040729.xml · derivative · entry 6 DOTSON JERROLD DUANE · CIK 0001388853 · VP, CFO AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,293 Underlying: Common Stock · 150,000 shares Expires 2029-05-23 F2 · kind: Represents stock options that were cancelled and returned to the Issuer in order to pay the exercise price associated with the exercise reported herein. F3 · derivative.exercise_date: 25% of the shares subject to this stock option vested May 23, 2019, with the the remaining shares vesting in 1/36th installments on each monthly anniversary thereafter. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:10 UTC |
DOTSON JERROLD DUANEVP, CFO AND SECRETARY
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-21-003391 · form4-07022021_040729.xml · derivative · entry 5 DOTSON JERROLD DUANE · CIK 0001388853 · VP, CFO AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2023-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:10 UTC |
DOTSON JERROLD DUANEVP, CFO AND SECRETARY
|
Exercise / conversionCommon Stock | 9,824 | $0.40 | $3,909.95 |
DisclosureSEC source: 0001415889-21-003391 · form4-07022021_040729.xml · nonDerivative · entry 4 DOTSON JERROLD DUANE · CIK 0001388853 · VP, CFO AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:10 UTC |
DOTSON JERROLD DUANEVP, CFO AND SECRETARY
|
Exercise / conversionCommon Stock | 78,918 | $1.00 | $78,918.00 |
DisclosureSEC source: 0001415889-21-003391 · form4-07022021_040729.xml · nonDerivative · entry 3 DOTSON JERROLD DUANE · CIK 0001388853 · VP, CFO AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:10 UTC |
DOTSON JERROLD DUANEVP, CFO AND SECRETARY
|
Exercise / conversionCommon Stock | 1,000 | $1.50 | $1,500.00 |
DisclosureSEC source: 0001415889-21-003391 · form4-07022021_040729.xml · nonDerivative · entry 2 DOTSON JERROLD DUANE · CIK 0001388853 · VP, CFO AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:10 UTC |
DOTSON JERROLD DUANEVP, CFO AND SECRETARY
|
GrantCommon Stock | 3,044 | $1.95 | $5,925.15 |
DisclosureSEC source: 0001415889-21-003391 · form4-07022021_040729.xml · nonDerivative · entry 1 DOTSON JERROLD DUANE · CIK 0001388853 · VP, CFO AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,044 F1 · shares: Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan on June 30, 2021 in a transaction exempt under Rule 16b-3(c). Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:39 UTC |
Cunningham Ann MichelleDirector · CHIEF COMMERCIAL OFFICER
|
GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $2.53 | $0.00 |
DisclosureSEC source: 0001415889-21-002243 · form4-05042021_010553.xml · derivative · entry 1 Cunningham Ann Michelle · CIK 0001764572 · Director · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-05-01 F1 · derivative.exercise_date: 25% of the stock options vest on the one-year anniversary of the grant date, with the remaining 75% vesting ratably on a monthly basis over the 36 months thereafter. Stock options were granted in connection with the Reporting Person's appointment to the Issuer's Board of Directors and pursuant to the Issuer's 2019 Omnibus Equity Incentive Plan. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 20:13 UTC |
Singh ShawnDirector · CHIEF EXECUTIVE OFFICER
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-21-002139 · form4-04272021_010440.xml · derivative · entry 3 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 20:13 UTC |
Singh ShawnDirector · CHIEF EXECUTIVE OFFICER
|
Exercise / conversionCommon Stock | 5,000 | $1.50 | $7,500.00 |
DisclosureSEC source: 0001415889-21-002139 · form4-04272021_010440.xml · nonDerivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 20:10 UTC |
Curley JoanneDirector
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001415889-21-002138 · form4-04272021_010425.xml · derivative · entry 1 Curley Joanne · CIK 0001857670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-04-23 F1 · derivative.exercise_date: 25% of the stock options vest on the one-year anniversary of the grant date, with the remaining 75% vesting ratably on a monthly basis over the 36 months thereafter. Stock options were granted in connection with the Reporting Person's appointment to the Issuer's Board of Directors and pursuant to the Issuer's 2019 Omnibus Equity Incentive Plan. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 19:03 UTC |
SAXE JON SDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-21-001607 · form4-03222021_040300.xml · derivative · entry 3 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2021-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 19:03 UTC |
SAXE JON SDirector
|
Exercise / conversionCommon Stock | 2,500 | $1.50 | $3,750.00 |
DisclosureSEC source: 0001415889-21-001607 · form4-03222021_040300.xml · nonDerivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 23:06 UTC |
Underdown Brian J.Director
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-21-001609 · form4-03222021_040356.xml · derivative · entry 2 Underdown Brian J. · CIK 0001526335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2021-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 23:06 UTC |
Underdown Brian J.Director
|
Exercise / conversionCommon Stock | 2,500 | $1.50 | $3,750.00 |
DisclosureSEC source: 0001415889-21-001609 · form4-03222021_040356.xml · nonDerivative · entry 1 Underdown Brian J. · CIK 0001526335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 22:17 UTC |
Ginski Mark JSENIOR VP, HEAD OF CMC
|
GrantStock Options (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-21-000508 · form4-02022021_020242.xml · derivative · entry 1 Ginski Mark J · CIK 0001843460 · SENIOR VP, HEAD OF CMC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-02-01 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares vest on the first anniversary of the grant date, and the remainder vests in 36 equal monthly installments thereafter over a period of three (3) years, becoming fully vested on February 1, 2025. Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 16:48 UTC |
SNODGRASS H. RALPHDirector · PRES./CHIEF SCIENTIFIC OFFICER
|
GrantCommon Stock | 5,000 | $0.45 | $2,260.50 |
DisclosureSEC source: 0001415889-21-000007 · form4-01042021_010136.xml · nonDerivative · entry 1 SNODGRASS H. RALPH · CIK 0001415876 · Director · PRES./CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,724 F1 · shares: Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan on December 31, 2020 in a transaction exempt under Rule 16b-3(c). Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 21:58 UTC |
Singh ShawnDirector · CHIEF EXECUTIVE OFFICER
|
GrantCommon Stock | 5,000 | $0.45 | $2,260.50 |
DisclosureSEC source: 0001415889-21-000020 · form4-01042021_010131.xml · nonDerivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,375 F1 · shares: Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan on December 31, 2020 in a transaction exempt under Rule 16b-3(c). Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 21:57 UTC |
DOTSON JERROLD DUANEVP, CFO AND SECRETARY
|
GrantCommon Stock | 5,000 | $0.45 | $2,260.50 |
DisclosureSEC source: 0001415889-21-000018 · form4-01042021_010114.xml · nonDerivative · entry 1 DOTSON JERROLD DUANE · CIK 0001388853 · VP, CFO AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan on December 31, 2020 in a transaction exempt under Rule 16b-3(c). Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 21:55 UTC |
Smith Mark AlanCHIEF MEDICAL OFFICER
|
GrantCommon Stock | 5,000 | $0.45 | $2,260.50 |
DisclosureSEC source: 0001415889-21-000016 · form4-01042021_010147.xml · nonDerivative · entry 1 Smith Mark Alan · CIK 0001677452 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan on December 31, 2020 in a transaction exempt under Rule 16b-3(c). Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 16:47 UTC |
GIN JERRY BDirector
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001415889-21-000005 · form4-01042021_010145.xml · derivative · entry 1 GIN JERRY B · CIK 0000901014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-12-30 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on December 31, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 16:54 UTC |
SAXE JON SDirector
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001415889-21-000014 · form4-01042021_010129.xml · derivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-12-30 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on December 31, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 16:48 UTC |
SNODGRASS H. RALPHDirector · PRES./CHIEF SCIENTIFIC OFFICER
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001415889-21-000007 · form4-01042021_010136.xml · derivative · entry 2 SNODGRASS H. RALPH · CIK 0001415876 · Director · PRES./CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-12-30 F2 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on December 31, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 21:58 UTC |
Singh ShawnDirector · CHIEF EXECUTIVE OFFICER
|
GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001415889-21-000020 · form4-01042021_010131.xml · derivative · entry 3 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-12-30 F2 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on December 31, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 21:59 UTC |
Cunningham Ann MichelleDirector
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001415889-21-000022 · form4-01042021_010143.xml · derivative · entry 1 Cunningham Ann Michelle · CIK 0001764572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-12-30 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on December 31, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 21:57 UTC |
DOTSON JERROLD DUANEVP, CFO AND SECRETARY
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001415889-21-000018 · form4-01042021_010114.xml · derivative · entry 2 DOTSON JERROLD DUANE · CIK 0001388853 · VP, CFO AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-12-30 F2 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on December 31, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 21:55 UTC |
Smith Mark AlanCHIEF MEDICAL OFFICER
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001415889-21-000016 · form4-01042021_010147.xml · derivative · entry 2 Smith Mark Alan · CIK 0001677452 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-12-30 F2 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on December 31, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 21:52 UTC |
Underdown Brian J.Director
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001415889-21-000012 · form4-01042021_010146.xml · derivative · entry 1 Underdown Brian J. · CIK 0001526335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-12-30 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on December 31, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 21:51 UTC |
MCPARTLAND MARK A.VP CORPORATE DEVELOPMENT
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001415889-21-000009 · form4-01042021_010119.xml · derivative · entry 1 MCPARTLAND MARK A. · CIK 0001620140 · VP CORPORATE DEVELOPMENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-12-30 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on December 31, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| August 21, 2020 Filed Aug 24, 2020 16:31 UTC |
SAXE JON SDirector
|
PurchaseCommon Stock | 30,000 | $0.69 | $20,700.00 |
DisclosureSEC source: 0001415889-20-002181 · form4-08242020_010800.xml · nonDerivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Jon S. Saxe and Myrna G. Marshall 1997 Trust Disclosed balance after: 50,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.678 to $0.697, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 17:35 UTC |
SNODGRASS H. RALPHDirector · PRES./CHIEF SCIENTIFIC OFFICER
|
GrantCommon Stock | 5,000 | $0.45 | $2,240.00 |
DisclosureSEC source: 0001415889-20-001767 · form4-07012020_020710.xml · nonDerivative · entry 1 SNODGRASS H. RALPH · CIK 0001415876 · Director · PRES./CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,724 F1 · shares: Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan ("ESPP") on June 30, 2020. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 21:33 UTC |
Smith Mark AlanCHIEF MEDICAL OFFICER
|
GrantCommon Stock | 5,000 | $0.45 | $2,240.00 |
DisclosureSEC source: 0001415889-20-001766 · form4-07012020_020750.xml · nonDerivative · entry 1 Smith Mark Alan · CIK 0001677452 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan ("ESPP") on June 30, 2020. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 21:20 UTC |
Singh ShawnDirector · CHIEF EXECUTIVE OFFICER
|
GrantCommon Stock | 5,000 | $0.45 | $2,240.00 |
DisclosureSEC source: 0001415889-20-001764 · form4-07012020_020757.xml · nonDerivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,375 F1 · shares: Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan ("ESPP") on June 30, 2020. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 21:28 UTC |
DOTSON JERROLD DUANEVP, CFO AND SECRETARY
|
GrantCommon Stock | 5,000 | $0.45 | $2,240.00 |
DisclosureSEC source: 0001415889-20-001765 · form4-07012020_020708.xml · nonDerivative · entry 1 DOTSON JERROLD DUANE · CIK 0001388853 · VP, CFO AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan ("ESPP") on June 30, 2020. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 17:10 UTC |
GIN JERRY BDirector
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001415889-20-001061 · form4-04272020_050406.xml · derivative · entry 1 GIN JERRY B · CIK 0000901014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-04-23 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on April 23, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 17:10 UTC |
SAXE JON SDirector
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001415889-20-001060 · form4-04272020_050401.xml · derivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-04-23 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on April 23, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 21:11 UTC |
MCPARTLAND MARK A.VP CORPORATE DEVELOPMENT
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001415889-20-001068 · form4-04272020_050447.xml · derivative · entry 1 MCPARTLAND MARK A. · CIK 0001620140 · VP CORPORATE DEVELOPMENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-04-23 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on April 23, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 17:10 UTC |
SNODGRASS H. RALPHDirector · PRES./CHIEF SCIENTIFIC OFFICER
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001415889-20-001065 · form4-04272020_050430.xml · derivative · entry 1 SNODGRASS H. RALPH · CIK 0001415876 · Director · PRES./CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-04-23 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on April 23, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 21:10 UTC |
Singh ShawnDirector · CHIEF EXECUTIVE OFFICER
|
GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001415889-20-001064 · form4-04272020_050423.xml · derivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-04-23 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on April 23, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 21:10 UTC |
DOTSON JERROLD DUANEVP, CFO AND SECRETARY
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001415889-20-001067 · form4-04272020_050442.xml · derivative · entry 1 DOTSON JERROLD DUANE · CIK 0001388853 · VP, CFO AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-04-23 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on April 23, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 21:10 UTC |
Smith Mark AlanCHIEF MEDICAL OFFICER
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001415889-20-001066 · form4-04272020_050436.xml · derivative · entry 1 Smith Mark Alan · CIK 0001677452 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-04-23 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on April 23, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 21:10 UTC |
Cunningham Ann MichelleDirector
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001415889-20-001063 · form4-04272020_050419.xml · derivative · entry 1 Cunningham Ann Michelle · CIK 0001764572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-04-23 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on April 23, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 21:10 UTC |
Underdown Brian J.Director
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001415889-20-001062 · form4-04272020_050412.xml · derivative · entry 1 Underdown Brian J. · CIK 0001526335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-04-23 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on April 23, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| November 20, 2019 Filed Nov 21, 2019 19:52 UTC |
SNODGRASS H. RALPHDirector · PRES./CHIEF SCIENTIFIC OFFICER
|
PurchaseCommon Stock | 15,000 | $0.34 | $5,100.00 |
DisclosureSEC source: 0001415889-19-001357 · form4-11212019_041106.xml · nonDerivative · entry 1 SNODGRASS H. RALPH · CIK 0001415876 · Director · PRES./CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · By H. Ralph Snodgrass Living Trust, dated 10/2/2008 Disclosed balance after: 15,000 Read SEC document |
| October 21, 2019 Filed Oct 22, 2019 17:00 UTC |
GIN JERRY BDirector
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001415889-19-001208 · form4-10222019_051020.xml · derivative · entry 1 GIN JERRY B · CIK 0000901014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-10-21 F1 · derivative.exercise_date: 25% of the Shares subject to the Option shall vest on date of grant October 21, 2019, and 1/24th of the remaining Shares subject to the Option shall vest on each monthly anniversary of the grant date thereafter. Read SEC document |
| October 21, 2019 Filed Oct 22, 2019 17:00 UTC |
SAXE JON SDirector
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001415889-19-001207 · form4-10222019_051003.xml · derivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-10-21 F1 · derivative.exercise_date: 25% of the Shares subject to the Option shall vest on date of grant October 21, 2019, and 1/24th of the remaining Shares subject to the Option shall vest on each monthly anniversary of the grant date thereafter. Read SEC document |
| October 21, 2019 Filed Oct 22, 2019 17:01 UTC |
SNODGRASS H. RALPHDirector · PRES./CHIEF SCIENTIFIC OFFICER
|
GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001415889-19-001212 · form4-10222019_051013.xml · derivative · entry 1 SNODGRASS H. RALPH · CIK 0001415876 · Director · PRES./CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2029-10-21 F1 · derivative.exercise_date: 25% of the Shares subject to the Option shall vest on date of grant October 21, 2019, and 1/24th of the remaining Shares subject to the Option shall vest on each monthly anniversary of the grant date thereafter. Read SEC document |
| October 21, 2019 Filed Oct 22, 2019 21:01 UTC |
Singh ShawnDirector · CHIEF EXECUTIVE OFFICER
|
GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001415889-19-001211 · form4-10222019_051000.xml · derivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2029-10-21 F1 · derivative.exercise_date: 25% of the Shares subject to the Option shall vest on date of grant October 21, 2019, and 1/24th of the remaining Shares subject to the Option shall vest on each monthly anniversary of the grant date thereafter. Read SEC document |
| October 21, 2019 Filed Oct 22, 2019 21:02 UTC |
DOTSON JERROLD DUANEVP, CFO AND SECRETARY
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001415889-19-001215 · form4-10222019_051046.xml · derivative · entry 1 DOTSON JERROLD DUANE · CIK 0001388853 · VP, CFO AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-10-21 F1 · derivative.exercise_date: 25% of the Shares subject to the Option shall vest on date of grant October 21, 2019, and 1/24th of the remaining Shares subject to the Option shall vest on each monthly anniversary of the grant date thereafter. Read SEC document |
| October 21, 2019 Filed Oct 22, 2019 21:01 UTC |
MCPARTLAND MARK A.VP CORPORATE DEVELOPMENT
|
GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001415889-19-001214 · form4-10222019_051035.xml · derivative · entry 1 MCPARTLAND MARK A. · CIK 0001620140 · VP CORPORATE DEVELOPMENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-10-21 F1 · derivative.exercise_date: 25% of the Shares subject to the Option shall vest on date of grant October 21, 2019, and 1/24th of the remaining Shares subject to the Option shall vest on each monthly anniversary of the grant date thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.